Self and Body Perception in Otoneurological Disorders: Translation and Validation of Measurement Scales
NCT ID: NCT05249283
Last Updated: 2025-09-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
612 participants
INTERVENTIONAL
2022-03-31
2024-10-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Several scales have been developed to measure DD, and the Cambridge Depersonalization Scale (CDS) appears to be the most relevant and consistent to characterize the clinical symptoms of these disorders as well as their duration and frequency. This scale, originally written in English, must be translated and validated according to standardized methods that include testing steps patients with dizziness and in individuals with no vestibular disorder.
Persistent postural-perceptual dizziness (PPPD) is a chronic, persistent vestibular syndrome generally preceded by acute vestibular disorders. The main symptoms are rotational dizziness, unsteadiness and / or non-rotating dizziness that are exacerbated by upright posture, walking, active or passive movement, and exposure to moving visual stimuli or complex visual patterns. To help diagnose this syndrome, a questionnaire was developed in Japan in 2019, the Niigata questionnaire, however no French version has yet been validated. Similarly, this scale needs to be validated in patient with PPPD and in control populations.
The main objective of this study is to validate the French translation of these two scales, the CDS questionnaire and the Niigata PPPD questionnaire, according to standard methods (forward translation, back translation, consensus).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
How do Individuals Respond to a Diagnosis of 3PD
NCT04260568
Psychological Ressources, Anxiodepressive Symptoms, Well-being and Therapeutical Observance in Parkinson's Disease
NCT05919628
Development of the Effectiveness of Rehabilitation Tools for Neurovisual Disorders in Patients With Posterior Cortical Atrophy
NCT04041089
Phenomenological and Psychopathological Factors Associated to Hallucinations in Parkinson's Disease
NCT03105401
Validation of a Diagnostic Self-assessment Scale Non-motor Fluctuations at the Parkinson's Patient
NCT02859805
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients
Patients with acute or chronic otoneurological disorders, presenting or having experienced dizziness and / or balance disorders
Questionnaire Measures
Patients will complete the following questionnaires: CDS questionnaire, Niigata PPPD questionnaire, HAD (Hospital Anxiety and Depression) scale and DHI (Dizziness Handicap Inventory)
Control subjects
Questionnaire Measures
Patients will complete the following questionnaires: CDS questionnaire, Niigata PPPD questionnaire, HAD (Hospital Anxiety and Depression) scale and DHI (Dizziness Handicap Inventory)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Questionnaire Measures
Patients will complete the following questionnaires: CDS questionnaire, Niigata PPPD questionnaire, HAD (Hospital Anxiety and Depression) scale and DHI (Dizziness Handicap Inventory)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 18 years
* Patient with acute or chronic otoneurological disorders
* Patient having or having experienced dizziness and / or balance disorders
* Patient with PPPD
* Fluency in French
* Having given free and informed written consent
* Being affiliated with or benefiting from social security
For control subjects:
* Age ≥ 18 years
* Fluency in French
* Having given free and informed written consent
* Being affiliated with or benefiting from social security.
Exclusion Criteria
-Past or present psychiatric and neurological disease (other than otoneurological or PPPD, as declared by the participant)
For control subjects:
-Past or present psychiatric and neurological disease (as declared by the participant) and vestibular and/or auditory system disorders (as declared by the participant)
For all participants:
* Persons still in a period of exclusion from another study and persons simultaneously participating in another study
* Subject to a measure for the protection of justice
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hôpital Européen Marseille
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Européen Marseille
Marseille, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21-44
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.